Physician profile
Lorimar Ramirez
NPI 1629277736
$4,298.23
in general payments reported to CMS, 2019-2025
28 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $251 · 2021: $864 · 2022: $583 · 2023: $668 · 2024: $1,387 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,483.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,253.24 | 2021-2025 | |
| Sobi, INC | $413.70 | 2021-2024 | |
| Servier Pharmaceuticals LLC | $350.15 | 2019-2025 | |
| Fennec Pharmaceuticals, INC. | $326.95 | 2024 | Pedmark |
| Alexion Pharmaceuticals, INC. | $299.03 | 2022-2024 | Ultomiris |
| Btg International INC. | $205.15 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $148.36 | 2024 | |
| Novartis Pharmaceuticals Corporation | $144.27 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $127.80 | 2023 | Clonoseq |
| Horizon Therapeutics Plc | $125.00 | 2021 | |
| Rare Disease Therapeutics, INC. | $114.61 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $101.25 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.05 | 2022-2023 | Advate, Gattex |
| Pfizer INC. | $100.65 | 2022-2024 | |
| Global Blood Therapeutics, INC. | $88.12 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $55.78 | 2020-2023 | Kristalose |
| Mirum Pharmaceuticals, INC. | $51.84 | 2022-2024 | Livmarli |
| Pharming Healthcare, INC. | $41.21 | 2022 | |
| Amgen INC. | $37.49 | 2019 | |
| Qol Medical, LLC | $36.55 | 2023 | Sucraid |
| Novo Nordisk INC | $30.69 | 2022-2023 | Esperoct |
| Bayer Healthcare Pharmaceuticals INC. | $28.57 | 2024 | |
| Duchesnay USA Incorporated | $23.92 | 2022 | |
| Day One Biopharmaceuticals | $22.33 | 2024 | Ojemda |
| Y-Mabs Therapeutics, INC. | $20.56 | 2024 | Danyelza |
| Nestle Healthcare Nutrition INC. | $17.08 | 2022 | |
| Sandoz INC. | $16.66 | 2023 | Hyrimoz |
| Uswm, LLC | $16.22 | 2024 | Iwilfin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorimar Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.